Ampio Pharmaceuticals, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
OTC.Pink
Ampio Pharmaceuticals has reached a proposed settlement in multiple shareholder derivative actions and demands, and is planning to dissolve the company.
OTC.Pink
Ampio Pharmaceuticals has announced its decision to voluntarily delist from the NYSE American and deregister its common stock with the SEC, citing high costs and non-compliance with listing requirements.
OTC.Pink
Ampio Pharmaceuticals has terminated its at-the-market equity distribution agreement with H.C. Wainwright & Co., LLC, effective March 6, 2024.
OTC.Pink
8-K: Ampio Pharmaceuticals' OA-201 Program Faces Setback as Preclinical Trial Fails to Show Efficacy
Ampio Pharmaceuticals' recent preclinical studies for its OA-201 osteoarthritis treatment failed to demonstrate the pain reduction benefits seen in earlier trials, jeopardizing its IND submission and future development.
OTC.Pink
Ampio Pharmaceuticals has filed a prospectus supplement to potentially sell up to $1.3 million of its common stock through an existing at-the-market offering agreement.
OTC.Pink
Ampio Pharmaceuticals has reached settlements in principle for a securities fraud class action and consolidated derivative actions, with costs expected to be covered by its D&O insurance.